摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(4-chloro-benzoylamino)-N-{4-[4-(5,6,7,8-tetrahydro-naphthalen-2-yl)-piperidin-1-yl]-butyl}-benzamide | 443142-43-6

中文名称
——
中文别名
——
英文名称
4-(4-chloro-benzoylamino)-N-{4-[4-(5,6,7,8-tetrahydro-naphthalen-2-yl)-piperidin-1-yl]-butyl}-benzamide
英文别名
4-[(4-chlorobenzoyl)amino]-N-[4-[4-(5,6,7,8-tetrahydronaphthalen-2-yl)piperidin-1-yl]butyl]benzamide
4-(4-chloro-benzoylamino)-N-{4-[4-(5,6,7,8-tetrahydro-naphthalen-2-yl)-piperidin-1-yl]-butyl}-benzamide化学式
CAS
443142-43-6
化学式
C33H38ClN3O2
mdl
——
分子量
544.137
InChiKey
YEQIZLKPYGICHL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    7
  • 重原子数:
    39
  • 可旋转键数:
    9
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.39
  • 拓扑面积:
    61.4
  • 氢给体数:
    2
  • 氢受体数:
    3

文献信息

  • Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
    申请人:——
    公开号:US20040077654A1
    公开(公告)日:2004-04-22
    The invention concerns Use of a compound of formula (I) or a physiologically acceptable salt, solvate or derivative thereof, in the manufacture of a medicament for the treatment of diseases ameliorated by LDL-r upregulation, to novel compounds and pharmaceutical compositions within the scope of formula (I).
    该发明涉及使用式(I)的化合物或其生理上可接受的盐、溶剂合物或衍生物,用于制造治疗通过LDL-r上调改善的疾病的药物,以及在式(I)范围内的新化合物和药物组合物。
  • Aryl piperidine derivatives as inducers of ldl-receptor expression
    申请人:——
    公开号:US20040072865A1
    公开(公告)日:2004-04-15
    The invention concerns a compound of formula (I), wherein Ar 1 represents phenyl, naphthyl or phenyl fused by a C 3-8 cycloalkyl, where each group is substituted by a group —O-Z and optionally one to three further groups independently represented by R 1 ; Ar 2 represents phenyl or 5-6 membered heteroaromatic group, where each group is optionally substituted by one to four groups independently selected from halogen, C 1-4 alkyl and C 1-4 alkoxy; Ar 3 represents a phenyl or a 5-6 membered heteroaromatic group, where each group is optionally substituted by one to four groups independently selected from hydroxy, alkyl, C 1-4 alkoxy, C 2-4 alkenyl, C 2-4 alkenyloxy, C 1-4 perfluoroalkoxy, C 1-4 acylamino or an electron withdrawing group; A represents —C(H)—; E represents —C 1-6 alkylene-; X represents —CON(H or C 1-4 alkyl)- or —N(H or C 1-4 alkyl)CO—; Y represents a direct link, —N(H or C 1-4 alkyl)CO— or —CON(H or C 1-4 alkyl)-; Z represents a metabolically labile group; R 1 represents halogen, —S(C 1-4 alkyl), —O—(C 0-4 alkylene)-R 2 or —(C 0-4 alkylene)-R 2 , where each alkylene group may additionally incorporate an oxygen in the chain, with the proviso that there are at least two carbon atoms between any chain heteroatoms; R 2 represents: i) hydrogen, C 1-4 perfluoroalkyl, C 2-3 alkenyl, ii) phenyl, naphthyl, a 5- or 6-membered heteroaromatic group or 1,2,3,4-tetrahydronaphthyl, optionally substituted by one or two halogen, hydroxy, C 1-4 alkyl, C 1-4 alkoxy groups, iii) C 3-8 cycloalkyl, a 3-7 membered heterocycloalkyl, iv) amino, C 1-4 alkylamino or di-C 1-4 alkylamino, with the proviso that there are at least two carbon atoms between any chain heteroatoms; and physiologically acceptable salts, solvates and pharmaceutical compositions thereof and their use in treating disorders associated with elevated circulating levels of LDL-cholesterol.
    本发明涉及公式(I)的化合物,其中Ar1代表苯基,基或被C3-8环烷基融合的苯基,其中每个基都被-O-Z基取代,且可以有一到三个进一步独立表示为R1的基;Ar2代表苯基或5-6成员杂环芳基,其中每个基可选地被从卤素,C1-4烷基和C1-4烷氧基中独立选择的一到四个基取代;Ar3代表苯基或5-6成员杂环芳基,其中每个基可选地被从羟基,烷基,C1-4烷氧基,C2-4烯基,C2-4烯氧基,C1-4全氟烷氧基,C1-4酰胺基或电子提取基中独立选择的一到四个基取代;A代表-C(H)-;E代表-C1-6烷基-;X代表-CON(H或C1-4烷基)-或-N(H或C1-4烷基)CO-;Y代表直接连接,-N(H或C1-4烷基)CO-或-CON(H或C1-4烷基)-;Z代表代谢易变基团;R1代表卤素,-S(C1-4烷基),-O-(C0-4烷基)-R2或-(C0-4烷基)-R2,其中每个烷基组可能在链中还包括一个氧,但前提是在任何链杂原子之间至少有两个碳原子;R2代表:i)氢,C1-4全氟烷基,C2-3烯基,ii)苯基,基,5-或6-成员杂环芳基或1,2,3,4-四氢萘基,可选地被一到两个卤素,羟基,C1-4烷基,C1-4烷氧基取代,iii)C3-8环烷基,3-7成员杂环环烷基,iv)基,C1-4烷基基或双C1-4烷基基,但前提是在任何链杂原子之间至少有两个碳原子;以及其生理上可接受的盐,溶剂化物和制药组合物及其用于治疗与LDL-胆固醇循环平升高相关的疾病。
  • Mass Labels
    申请人:Hamon Christian
    公开号:US20100178710A1
    公开(公告)日:2010-07-15
    A mass label for labelling and detecting a biological molecule by mass spectroscopy, which label comprises the following structure: X-L-M wherein X is a mass marker moiety comprising the following group: formula (I), wherein the cyclic unit is aromatic or aliphatic and comprises from 0-3 double bonds independently between any two adjacent atoms; each Z is independently N, N(R 1 ), C(R 1 ), CO, CO(R 1 ), C(R 1 ) 2 , O or S; X is N, C or C(R 1 ); each R 1 is independently H, a substituted or unsubstituted straight or branched C 1 -C 6 alkyl group, a substituted or unsubstituted aliphatic cyclic group, a substituted or unsubstituted aromatic group or a substituted or unsubstituted heterocyclic group; and y is an integer from 0-10, L is a cleavable linker comprising an amide bond and M is a mass normalization moiety.
    一种用于质谱法标记和检测生物分子的质量标记,该标记包括以下结构:X-L-M,其中X是质量标记基团,包括以下组:公式(I),其中环状单元是芳香族或脂肪族,并且在任意两个相邻原子之间独立地包含0-3个双键;每个Z独立地是N,N(R1),C(R1),CO,CO(R1),C(R1)2,O或S;X为N,C或C(R1);每个R1独立地是H,取代或未取代的直链或支链C1-C6烷基,取代或未取代的脂肪环状基团,取代或未取代的芳香族基团或取代或未取代的杂环基团;y为0-10的整数,L是一个可断链的连接基团,包括一个酰胺键,M是一个质量归一化基团。
  • ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION
    申请人:GLAXO GROUP LIMITED
    公开号:EP1351935A1
    公开(公告)日:2003-10-15
  • ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION
    申请人:GLAXO GROUP LIMITED
    公开号:EP1351936A1
    公开(公告)日:2003-10-15
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫